EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Combination of Upadacitinib and Risankizumab in Refractory Crohn's Disease

Clara Ramos‐Belinchon, Nikolas Plevris, Ian Arnott, Shahida Din, Jonathan Blackwell, Charlie W. Lees

JCC Plus · 2026-05 · 1 (3)

DOI: 10.1002/jcc5.70034 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCC Plus, online erschienen am 07.04.2026. Verfasst von Clara Ramos‐Belinchon und 5 weiteren Autor:innen. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UK Research and Innovation.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim Dual targeted therapies (DTT) are a promising off‐label approach for the treatment of refractory Crohn's disease (CD). Upadacitinib and risankizumab are approved for the treatment of moderate to severe CD. Our aim was to evaluate the effectiveness and safety of a combination of upadacitinib and risankizumab for refractory CD.

Methods

In this retrospective, observational study we assessed n = 15 CD patients who received the combination upadacitinib and risankizumab at the Edinburgh IBD Unit, Scotland. All patients included had a minimum overlap of 8 weeks. The primary outcome was steroid‐free clinical response (SFCR) at 12 weeks defined as a decrease in Harvey Bradshaw Index (HBI) ≥ 3 and/or HBI < 5; if not available, a reduction of Physician Global Assessment (PGA) ≥ 1 was also considered as a response. Secondary outcomes included clinical remission (HBI < 5 or considered by PGA if HBI was not available), C‐reactive protein (CRP) remission (CRP≤ 5 mg/L) and faecal calprotectin (FC) remission (FC < 250 μg/g) at 12 weeks. Additional secondary outcomes were persistence at 24 and 52 weeks in patients with planned long‐term DTT, and successful withdrawal in patients with planned short‐term DTT. Safety outcomes were also recorded.

Results

Fifteen patients were included with a median of 3 prior advanced therapies (IQR 2–5). SFCR was achieved in 53% (8/15). Steroid‐free clinical remission, CRP and FC remission were achieved in 40% (6/15), 27% (4/15) and 27% (4/15) of the total patients, respectively. No treatment‐related serious adverse events were observed.

Conclusions

In this case series, combination upadacitinib and risankizumab demonstrated, short‐term effectiveness and safety in a highly refractory cohort of CD patients.

Förderung

  • UK Research and Innovation

Zitieren

APA

Ramos‐Belinchon, C., Plevris, N., Arnott, I., Din, S., Blackwell, J., & Lees, C. W. (2026). Combination of Upadacitinib and Risankizumab in Refractory Crohn's Disease. JCC Plus, 1(3). https://doi.org/10.1002/jcc5.70034

Vancouver

Ramos‐Belinchon C, Plevris N, Arnott I, Din S, Blackwell J, Lees CW. Combination of Upadacitinib and Risankizumab in Refractory Crohn's Disease. JCC Plus. 2026;1(3). doi:10.1002/jcc5.70034

BibTeX
@article{RamosBelinchon2026,
  author = {Ramos‐Belinchon, Clara and Plevris, Nikolas and Arnott, Ian and Din, Shahida and Blackwell, Jonathan and Lees, Charlie W.},
  title = {Combination of Upadacitinib and Risankizumab in Refractory Crohn's Disease},
  journal = {JCC Plus},
  year = {2026},
  volume = {1},
  number = {3},
  doi = {10.1002/jcc5.70034}
}
Kostenlos starten →